Pathways to gene therapy in rheumatoid arthritis

Area of Science:

• Biotechnology
• Immunology
• Rheumatology

Background:

• Rheumatoid arthritis (RA) is a chronic autoimmune disease requiring novel therapeutic strategies.
• Gene therapy presents a promising avenue for RA treatment by introducing therapeutic genes.
• Current research focuses on delivering genes encoding secreted proteins with antiarthritic properties.

Purpose of the Study:

• To explore the potential of gene therapy for treating rheumatoid arthritis.
• To evaluate different gene delivery methods and vectors for RA treatment.
• To assess the efficacy of gene therapy in preclinical models of arthritis.

Main Methods:

• Investigated local and systemic gene delivery strategies.
• Compared ex vivo and in vivo gene transfer techniques.
• Tested various vectors including retrovirus, adenovirus, herpes simplex virus, liposomes, and naked DNA for joint gene delivery.
• Utilized ex vivo retroviral gene transfer of human interleukin-1 receptor antagonist (hIL-1RA) in animal models.

Main Results:

• Adenovirus showed potential for in vivo synovium gene delivery but caused inflammatory responses.
• Ex vivo retroviral gene transfer achieved high intra-articular transgene expression in animal models.
• Gene therapy using hIL-1RA demonstrated promising antiarthritic effects in preclinical studies.

Conclusions:

• Gene therapy holds significant potential for rheumatoid arthritis treatment.
• Ex vivo gene transfer using retroviruses is a viable strategy for achieving therapeutic gene expression in joints.
• Successful preclinical results have led to FDA approval for the first human arthritis gene therapy trial.